Cargando…

Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis

(1) Background: Systemic granulomatosis developed in a context of malignancy has already been reported. Our objective was to describe the clinical, radiological, functional, biological, and evolutive characteristics of sarcoidosis-like cancer-associated granulomatosis (SLCAG) and to compare them to...

Descripción completa

Detalles Bibliográficos
Autores principales: Pastré, Jean, Bouvry, Diane, Juvin, Karine, Benattia, Amira, Annesi-Maesano, Isabella, Valeyre, Dominique, Nunes, Hilario, Israël-Biet, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124510/
https://www.ncbi.nlm.nih.gov/pubmed/34063172
http://dx.doi.org/10.3390/jcm10091988
_version_ 1783693226040885248
author Pastré, Jean
Bouvry, Diane
Juvin, Karine
Benattia, Amira
Annesi-Maesano, Isabella
Valeyre, Dominique
Nunes, Hilario
Israël-Biet, Dominique
author_facet Pastré, Jean
Bouvry, Diane
Juvin, Karine
Benattia, Amira
Annesi-Maesano, Isabella
Valeyre, Dominique
Nunes, Hilario
Israël-Biet, Dominique
author_sort Pastré, Jean
collection PubMed
description (1) Background: Systemic granulomatosis developed in a context of malignancy has already been reported. Our objective was to describe the clinical, radiological, functional, biological, and evolutive characteristics of sarcoidosis-like cancer-associated granulomatosis (SLCAG) and to compare them to those of sarcoidosis. (2) Methods: 38 patients with a biopsy-proven SLCAG developed after a diagnostic of malignancy were included. The control group consisted of sarcoidosis patients matched for age, sex, and radiologic stage. Clinical, biological, physiological, radiological, and outcome data were collected. (3) Results: The mean age of SLCAG patients was 51 ± 14 years. They were diagnosed within 15 ± 14 months of the cancer diagnosis (breast cancer most frequently). All SLCAG patients presented a thoracic involvement, extrathoracic locations were observed in 32% of subjects. SLCAG was more often asymptomatic than sarcoidosis (p < 0.0001). During follow-up, systemic treatment was less often required in SLCAG than in sarcoidosis (58% vs. 32%, p = 0.04 respectively) and SLCAG were characterized by a significantly less severe progression profile according to the Sarcoid Clinical Activity Classification, with a complete recovery more frequent at 5 years (p = 0.03). (4) Conclusion: This case-control study shows that SLCAG differs from sarcoidosis with a significantly more benign course. These results might argue for true differences in the physiopathology, which remain to be elucidated.
format Online
Article
Text
id pubmed-8124510
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81245102021-05-17 Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis Pastré, Jean Bouvry, Diane Juvin, Karine Benattia, Amira Annesi-Maesano, Isabella Valeyre, Dominique Nunes, Hilario Israël-Biet, Dominique J Clin Med Article (1) Background: Systemic granulomatosis developed in a context of malignancy has already been reported. Our objective was to describe the clinical, radiological, functional, biological, and evolutive characteristics of sarcoidosis-like cancer-associated granulomatosis (SLCAG) and to compare them to those of sarcoidosis. (2) Methods: 38 patients with a biopsy-proven SLCAG developed after a diagnostic of malignancy were included. The control group consisted of sarcoidosis patients matched for age, sex, and radiologic stage. Clinical, biological, physiological, radiological, and outcome data were collected. (3) Results: The mean age of SLCAG patients was 51 ± 14 years. They were diagnosed within 15 ± 14 months of the cancer diagnosis (breast cancer most frequently). All SLCAG patients presented a thoracic involvement, extrathoracic locations were observed in 32% of subjects. SLCAG was more often asymptomatic than sarcoidosis (p < 0.0001). During follow-up, systemic treatment was less often required in SLCAG than in sarcoidosis (58% vs. 32%, p = 0.04 respectively) and SLCAG were characterized by a significantly less severe progression profile according to the Sarcoid Clinical Activity Classification, with a complete recovery more frequent at 5 years (p = 0.03). (4) Conclusion: This case-control study shows that SLCAG differs from sarcoidosis with a significantly more benign course. These results might argue for true differences in the physiopathology, which remain to be elucidated. MDPI 2021-05-05 /pmc/articles/PMC8124510/ /pubmed/34063172 http://dx.doi.org/10.3390/jcm10091988 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pastré, Jean
Bouvry, Diane
Juvin, Karine
Benattia, Amira
Annesi-Maesano, Isabella
Valeyre, Dominique
Nunes, Hilario
Israël-Biet, Dominique
Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis
title Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis
title_full Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis
title_fullStr Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis
title_full_unstemmed Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis
title_short Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis
title_sort sarcoidosis-like cancer-associated granulomatosis: characteristics and a case-control comparison with sarcoidosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124510/
https://www.ncbi.nlm.nih.gov/pubmed/34063172
http://dx.doi.org/10.3390/jcm10091988
work_keys_str_mv AT pastrejean sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis
AT bouvrydiane sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis
AT juvinkarine sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis
AT benattiaamira sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis
AT annesimaesanoisabella sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis
AT valeyredominique sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis
AT nuneshilario sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis
AT israelbietdominique sarcoidosislikecancerassociatedgranulomatosischaracteristicsandacasecontrolcomparisonwithsarcoidosis